Alberta MDs irate over prescribing privacy issue

Sibbald, Barbara
November 2003
CMAJ: Canadian Medical Association Journal;11/11/2003, Vol. 169 Issue 10, p1066
Academic Journal
Reports on the decision of IMS Health to cancel its opt-out policy, which would prevent it from disclosing prescribing data from pharmacies to pharmaceutical companies. Influence of the Alberta Medical Association on the decision; Privacy issues associated with disseminating prescription information.


Related Articles

  • PRESCRIPTION DRUG ABUSE. Stark, Pete // USA Today Magazine;Jul91, Vol. 120 Issue 2554, p88 

    Presents a case for the establishment of a national accountability program for controlled drug prescriptions in the U.S. Scope of the Controlled Substances Act; Tasks and responsibilities of the Drug Abuse Warning Network; Forms of Medicaid fraud; Proposed accountable prescription program.

  • Rx drugs post slowest growth since 1961: IMS Health. McGuire, Stephen // Medical Marketing & Media;Apr2008, Vol. 43 Issue 4, p8 

    The article reports on the lowest sales growth of prescription drugs in the U.S. pharmaceutical industry since 1961. Reported by IMS Health Inc., the total prescription sales of drugs increased to $286.5 billion in 2007, with slow sales rate resulting from loss of brand exclusivity, few product...

  • The Pharma Top 50.  // Pharmaceutical Technology Europe;Jul2009, Vol. 21 Issue 7, p43 

    The article reports on the performance of the top 50 pharmaceutical companies in Europe. It highlights that the top 50 pharmaceutical companies reported $558 billion prescription drug sales in 2008. According to the article the, the rankings for the pharmaceutical companies are based on their...

  • Going Off Patent: Standing Pat to Getting Out. O'Connell, Brian // BioPharm International;Jan2004, Vol. 17 Issue 1, p26 

    Focuses on the increase competition from generic drugs according to IMS Health Inc. and Reuters. Availability of prescription and generic drugs; Percentage of increase in sales of generic drugs in 2004; Priorities of government regulators regarding drug patents.

  • Pharmaceutical sales increased during recession. Kondro, Wayne // CMAJ: Canadian Medical Association Journal;5/18/2010, Vol. 182 Issue 8, pE341 

    The article offers information on the increased sales in the Canadian pharmaceutical industry. According to IMS Health Inc. sale of Canadian retail pharmacies increased by 6.1 percent. It also highlights the increase in the generic drugs by 54.3 percent. IMS Health Inc. data states that...

  • GPs reject drug waste criticism. Pedder, Cato // Pulse;5/24/2007, Vol. 67 Issue 20, p10 

    The article focuses on the rejection of general practitioners (GPs) concerning drug waste criticism in Great Britain. GPs responded angrily to the accusation due to their wasteful prescription, ramping up the pressure for switching to cheaper drugs. The National Health Service could save at...

  • TYPICAL ENTRY.  // MPR - Pediatricians' Edition;Spring/Summer2013, Vol. 24 Issue 1, pA-8 

    The article provides key labeling information when prescribing pharmaceutical products and formulation. It offers information on the brand name of the product as well as the name of the company to contact and the generic name of the active ingredients and clinically relevant excipients. It also...

  • Specialty meds stay strong amid Rx slowdown. Frederick, Jim // Drug Store News;3/2/2009, Vol. 31 Issue 3, p53 

    The article reports on the increase prominence of special medicines despite the decreasing demand of drug prescription in the U.S. The author states that therapies derive from accelerated research and development techniques are gaining prominence due to its effectiveness. IMS SVP Murray Aitken...

  • US spending on prescription drugs rose 19% in 2000. Charatan, Fred // BMJ: British Medical Journal (International Edition);05/19/2001, Vol. 322 Issue 7296, p1198 

    Reports that spending on prescription drugs in the United States increased in 2000. Findings by the National Institute for Health Care Management Foundation; Contribution of aggressive marketing strategies implemented by drug companies to the growth; Factors contributing to the rise in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics